AU2003260401A1 - Use of thiazolidinedione derivatives as aldose reductase inhibitors - Google Patents

Use of thiazolidinedione derivatives as aldose reductase inhibitors

Info

Publication number
AU2003260401A1
AU2003260401A1 AU2003260401A AU2003260401A AU2003260401A1 AU 2003260401 A1 AU2003260401 A1 AU 2003260401A1 AU 2003260401 A AU2003260401 A AU 2003260401A AU 2003260401 A AU2003260401 A AU 2003260401A AU 2003260401 A1 AU2003260401 A1 AU 2003260401A1
Authority
AU
Australia
Prior art keywords
reductase inhibitors
aldose reductase
thiazolidinedione derivatives
thiazolidinedione
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003260401A
Inventor
Gerard Botton
Philippe Durbin
Didier Mesangeau
Gerard Moinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2003260401A1 publication Critical patent/AU2003260401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003260401A 2002-09-30 2003-08-11 Use of thiazolidinedione derivatives as aldose reductase inhibitors Abandoned AU2003260401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/12088 2002-09-30
FR0212088A FR2845003A1 (en) 2002-09-30 2002-09-30 USE OF THIAZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE
PCT/EP2003/008888 WO2004028537A1 (en) 2002-09-30 2003-08-11 Use of thiazolidinedione derivatives as aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
AU2003260401A1 true AU2003260401A1 (en) 2004-04-19

Family

ID=31985343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260401A Abandoned AU2003260401A1 (en) 2002-09-30 2003-08-11 Use of thiazolidinedione derivatives as aldose reductase inhibitors

Country Status (3)

Country Link
AU (1) AU2003260401A1 (en)
FR (1) FR2845003A1 (en)
WO (1) WO2004028537A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090033886A (en) * 2006-07-25 2009-04-06 알콘 리서치, 리미티드 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933355A (en) * 1988-04-14 1990-06-12 Sankyo Company Limited Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
FR2749583B1 (en) * 1996-06-07 1998-08-21 Lipha NOVEL SUBSTITUTED THIAZOLIDINE -2,4- DIONE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Also Published As

Publication number Publication date
FR2845003A1 (en) 2004-04-02
WO2004028537A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2003303231A1 (en) Benzoxazines and derivatives thereof as inhibitors of pi3ks
AU2003251559A1 (en) Heterocyclic inhibitors of kinases
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003261434A1 (en) Iminothiazolidinones as inhibitors of hcv replication
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
AU2003237121A1 (en) Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003218758A1 (en) Derivatives of 1-phenyl-3-phenylpyrazole as herbicides
AU2003263345A1 (en) Sulphonamide derivatives and their use as tace inhibitors
AU2003255376A1 (en) Piperidine-derivatives as pde4 inhibitors
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
IL183188A0 (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
AU2003243603A1 (en) Methods and compositions involving aldose reductase inhibitors
AU2003243318A1 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2002340031A1 (en) Compounds useful as reversible inhibitors of cysteine proteases
AU2003302238A1 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003249531A1 (en) Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003272719A1 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
AU2003218107A1 (en) C12-cyano epothilone derivatives
AU2002238103A1 (en) Use of beta-lactamase inhibitors as neuroprotectants
PL378760A1 (en) Oxazole derivatives as inhibitors of cyclooxygenase
AU2003214609A1 (en) Derivatives of isoflavones
AU2003250858A1 (en) Use of organic compounds
AU2003295638A1 (en) NOVEL INHIBITORS OF Beta-LACTAMASE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase